The current landscape of Lp(a) is characterised by a convergence of scientific maturity and implementation gaps. While the causal role of Lp(a) in cardiovascular disease is well established, its translation into policy and practice remains inconsistent. Recent international initiatives, including the Global Lp(a) Summit and the Brussels International Declaration on Lp(a), have created important momentum by consolidating scientific consensus and guidelines, and articulating a shared policy agenda. As outlined in the Brussels Declaration, there is a clear need to move from awareness to systematic implementation. At the same time, the development of targeted therapies is advancing rapidly, reinforcing the urgency of establishing appropriate diagnostic and care frameworks.
The overarching objective of the Taskforce is to ensure that Lp(a) is systematically integrated into cardiovascular prevention frameworks, from population-level risk identification to clinical management and policy planning. This objective is operationalised through the development and implementation of a global roadmap for Lp(a), providing a structured approach to translating evidence and policy commitments into practice.
A central priority is the integration of Lp(a) measurement into routine clinical and public health practice. Given that Lp(a) levels are genetically determined and stable over time, a single measurement can in most persons provide lifelong information on risk. Building on the calls to action articulated in the Brussels Declaration, the Taskforce supports the adoption of policies that enable broad and equitable access to testing, particularly through incorporation into existing screening and prevention programmes.
Ensuring that Lp(a) is consistently reflected in national and international frameworks is essential for sustainable implementation. This includes its incorporation into cardiovascular strategies, clinical guidelines, and risk assessment models. The Taskforce works to translate the outcomes of global initiatives into concrete policy measures, supporting alignment across jurisdictions and reducing fragmentation in implementation.
Although the scientific basis for Lp(a) as a causal risk factor is well established, further work is needed to support policy and implementation decisions. This includes generating and consolidating evidence on epidemiology, disease burden, and health economic impact. The Taskforce contributes to this effort by supporting research initiatives and promoting the use of data generated through international collaborations and expert convenings, including those initiated through the Global Summit process.
The anticipated introduction of Lp(a)-targeted therapies represents a significant development in cardiovascular medicine. However, their effective implementation will depend on the readiness of health systems. As highlighted in international roadmap discussions, this includes the availability of diagnostic infrastructure, the definition of care pathways, and the establishment of reimbursement and access mechanisms.
Addressing Lp(a) requires coordinated action across multiple stakeholders, including researchers, clinicians, policymakers, regulators, and patient organisations. Through its convening role and its connection to major international initiatives, the Taskforce provides a platform for sustained alignment, enabling shared priorities, consistent messaging, and coordinated implementation efforts.
The integration of Lp(a) into policy and practice represents a critical opportunity to strengthen cardiovascular prevention. The foundations have been established through key initiatives and growing consensus; the priority now is implementation. By advancing the global roadmap and building on existing international momentum, the Lp(a) International Taskforce aims to support this transition and contribute to measurable improvements in population health outcomes.